Trial Profile
A study of cardiological monitoring in chronic myeloid leukemia patients treated with nilotinib and dasatinib, in the second line of treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 24 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology